



**This Bill Analysis  
reflects the contents  
of the bill as it was  
presented in  
committee.**

# HOUSE BILL 287: Educate Patients About Opioid Antagonists.

2023-2024 General Assembly

---

<b>Committee:</b>	House Health. If favorable, re-refer to Rules, Calendar, and Operations of the House	<b>Date:</b>	March 21, 2023
<b>Introduced by:</b>	Reps. Sasser, K. Baker, White, Potts	<b>Prepared by:</b>	Jessica Boney Staff Attorney
<b>Analysis of:</b>	First Edition		

---

**OVERVIEW:** *House Bill 287 would require practitioners and pharmacies to educate patients about the dangers of opioids, the prevention of overdoses, and the availability of opioid antagonists for reversal of opioid overdoses when receiving a prescription for a Schedule II controlled substance.*

### BILL ANALYSIS:

House Bill 287 would require practitioners to provide information about the following to patients when prescribing a Schedule II controlled substance:

- Potential dangers of opioids;
- Overdose prevention;
- Availability and use of opioid antagonists to reverse opioid overdoses.

If treating a minor, a practitioner would be required to supply the information to the minor's guardian.

A pharmacy would be required to provide the same information when dispensing a Schedule II controlled substance, and to post signage with the information in a conspicuous place.

A practitioner's liability would not be limited for negligent treatment of a patient and failure to follow the requirements would not create a private right of action.

**EFFECTIVE DATE:** This act would be effective October 1, 2023.

Jeffrey Hudson  
Director



Legislative Analysis  
Division  
919-733-2578